GANX · Gain Therapeutics, Inc.
$1.91
-0.10 (-4.75%)
At close · Aug 25
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report.”View the 10-Q filed Aug 11, 2026
Market Cap
$87.51M
Shares
43.64M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Eric I. Richman | Former Chief Executive Officer | $1,271,732 |
| Matthias Alder | Chief Executive Officer and former Chief Operating Officer | $1,075,990 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Matthias Alder | Chief Executive Officer and former Chief Operating Officer | $954,034 |
| Eric I. Richman | Former Chief Executive Officer | $600,165 |
| Salvatore Calabrese | Former Chief Financial Officer | $345,389 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Eric Richman | Board of Directors | Resigned | 2025-10-09 |
| Gene Mack | member of the Company's board of directors | Appointed | 2025-01-07 |
| Gene Mack | Chief Financial Officer | Resigned | 2025-01-07 |
| Gene Mack | President and Chief Executive Officer | Appointed | 2025-01-07 |
| Gene Mack | Interim Chief Executive Officer | Appointed | 2024-06-28 |
| Dr. Khalid Islam | Executive Chairman of the Board | Appointed | 2024-06-28 |
| Matthias Alder | Board | Resigned | 2024-06-28 |
| Matthias Alder | Chief Executive Officer | Terminated | 2024-06-28 |
| Gene Mack | Principal Financial Officer | Appointed | 2024-04-08 |
| Gene Mack | Secretary | Appointed | 2024-04-08 |
| Gene Mack | Chief Financial Officer | Appointed | 2024-04-08 |
| C. Evan Ballantyne | Chief Financial Officer | Resigned | 2024-02-22 |
| Salvatore Calabrese | Chief Financial Officer | Terminated | 2023-04-28 |
| C. Evan Ballantyne | Chief Financial Officer | Appointed | 2023-04-12 |
| Salvatore Calabrese | Chief Financial Officer | Terminated | 2023-04-12 |
| C. Evan Ballantyne | Chief Financial Officer | Appointed | 2023-04-12 |
| Gianluca Fuggetta | Principal Accounting Officer | Appointed | 2022-12-16 |
| Matthias Alder | member of the Board | Appointed | 2022-09-20 |
| Matthias Alder | President and Chief Executive Officer | Appointed | 2022-09-20 |
| Eric Richman | Chief Executive Officer | Resigned | 2022-09-20 |
| Matthias Alder | Chief Operating Officer | Appointed | 2021-10-20 |
Key facts
CIK
1819411
CUSIP
36269B105
13F (30d)
45 filings
45 filers
Visit website
Investor relations